1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
2
|
Whelan J, McTiernan A, Cooper N, Wong YK,
Francis M, Vernon S and Strauss SJ: Incidence and survival of
malignant bone sarcomas in England 1979–2007. Int J Cancer.
131:E508–E517. 2012. View Article : Google Scholar
|
3
|
Longhi A, Errani C, De Paolis M, Mercuri M
and Bacci G: Primary bone osteosarcoma in the pediatric age: State
of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Eilber FR and Rosen G: Adjuvant
chemotherapy for osteosarcoma. Semin Oncol. 16:312–322.
1989.PubMed/NCBI
|
5
|
Pápai Z, Féja CN, Hanna EN, Sztán M, Oláh
E and Szendrôi M: P53 overexpression as an indicator of overall
survival and response to treatment in osteosarcomas. Pathol Oncol
Res. 3:15–19. 1997. View Article : Google Scholar : PubMed/NCBI
|
6
|
Sakamoto A and Iwamoto Y: Current status
and perspectives regarding the treatment of osteosarcoma:
Chemotherapy. Rev Recent Clin Trials. 3:228–231. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:1352–1362. 2014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Lim LP, Glasner ME, Yekta S, Burge CB and
Bartel DP: Vertebrate microRNA genes. Science. 299:15402003.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar
|
11
|
Tagawa H and Seto M: A microRNA cluster as
a target of genomic amplification in malignant lymphoma. Leukemia.
19:2013–2016. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17-92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
14
|
Mendell JT: miRiad roles for the miR-17-92
cluster in development and disease. Cell. 133:217–222. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Olive V, Bennett MJ, Walker JC, Ma C,
Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ and He L: miR-19
is a key oncogenic component of mir-17-92. Genes Dev. 23:2839–2849.
2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chen YJ, Wu H, Zhu JM, Li XD, Luo SW, Dong
L, Liu TT and Shen XZ: MicroRNA-18a modulates P53 expression by
targeting IRF2 in gastric cancer patients. J Gastroenterol Hepatol.
31:155–163. 2016. View Article : Google Scholar
|
17
|
Speidel D: Transcription-independent p53
apoptosis: An alternative route to death. Trends Cell Biol.
20:14–24. 2010. View Article : Google Scholar
|
18
|
Chen H, Zhou L, Wu X, Li R, Wen J, Sha J
and Wen X: The PI3K/AKT pathway in the pathogenesis of prostate
cancer. Front Biosci. 21:1084–1091. 2016. View Article : Google Scholar
|
19
|
Wang KC, Botting KJ, Zhang S, McMillen IC,
Brooks DA and Morrison JL: Akt signaling as a mediator of cardiac
adaptation to low birth weight. J Endocrinol. 233:R81–R94. 2017.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Lu Y, Thomson JM, Wong HY, Hammond SM and
Hogan BL: Transgenic overexpression of the microRNA miR-17-92
cluster promotes proliferation and inhibits differentiation of lung
epithelial progenitor cells. Dev Biol. 310:442–453. 2007.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Luo Z, Dai Y, Zhang L, Jiang C, Li Z, Yang
J, McCarthy JB, She X, Zhang W, Ma J, et al: miR-18a promotes
malignant progression by impairing microRNA biogenesis in
nasopharyngeal carcinoma. Carcinogenesis. 34:415–425. 2013.
View Article : Google Scholar
|
22
|
Zhang W, Lei C, Fan J and Wang J: miR-18a
promotes cell proliferation of esophageal squamous cell carcinoma
cells by increasing cylin D1 via regulating PTEN-PI3K-AKT-mTOR
signaling axis. Biochem Biophys Res Commun. 477:144–149. 2016.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Hsu TI, Hsu CH, Lee KH, Lin JT, Chen CS,
Chang KC, Su CY, Hsiao M and Lu PJ: MicroRNA-18a is elevated in
prostate cancer and promotes tumorigenesis through suppressing STK4
in vitro and in vivo. Oncogenesis. 3:e992014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Wu W, Zhou X, Yu T, Bao Z, Zhi T, Jiang K,
Nie E, Wang Y, Zhang J and You Y: The malignancy of miR-18a in
human glioblastoma via directly targeting CBX7. Am J Cancer Res.
7:64–76. 2017.PubMed/NCBI
|
25
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Fenger JM, Roberts RD, Iwenofu OH, Bear
MD, Zhang X, Couto JI, Modiano JF, Kisseberth WC and London CA:
miR-9 is overexpressed in spontaneous canine osteosarcoma and
promotes a metastatic phenotype including invasion and migration in
osteoblasts and osteosarcoma cell lines. BMC Cancer. 16:7842016.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Baumhoer D: Molecular characterization of
osteosarcomas. Pathologe. 34(Suppl 2): 260–263. 2013.In German.
View Article : Google Scholar
|
28
|
Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li
T: miRecords: An integrated resource for microRNA-target
interactions. Nucleic Acids Res. 37(Database): D105–D110. 2009.
View Article : Google Scholar
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
30
|
Ji J and Wang XW: New kids on the block:
Diagnostic and prognostic microRNAs in hepatocellular carcinoma.
Cancer Biol Ther. 8:1686–1693. 2009. View Article : Google Scholar : PubMed/NCBI
|
31
|
Giráldez MD, Lozano JJ, Ramírez G, Hijona
E, Bujanda L, Castells A and Gironella M: Circulating microRNAs as
biomarkers of colorectal cancer: Results from a genome-wide
profiling and validation study. Clin Gastroenterol Hepatol.
11:681–8.e3. 2013. View Article : Google Scholar
|
32
|
Lawrie CH: MicroRNA expression in
lymphoma. Expert Opin Biol Ther. 7:1363–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
33
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Schulte JH, Horn S, Otto T, Samans B,
Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L,
Buettner R, et al: MYCN regulates oncogenic microRNAs in
neuroblastoma. Int J Cancer. 122:699–704. 2008. View Article : Google Scholar
|
35
|
Woods K, Thomson JM and Hammond SM: Direct
regulation of an oncogenic micro-RNA cluster by E2F transcription
factors. J Biol Chem. 282:2130–2134. 2007. View Article : Google Scholar
|
36
|
Guil S and Cáceres JF: The multifunctional
RNA-binding protein hnRNP A1 is required for processing of miR-18a.
Nat Struct Mol Biol. 14:591–596. 2007. View Article : Google Scholar : PubMed/NCBI
|
37
|
Li H, Bian C, Liao L, Li J and Zhao RC:
miR-17-5p promotes human breast cancer cell migration and invasion
through suppression of HBP1. Breast Cancer Res Treat. 126:565–575.
2011. View Article : Google Scholar
|
38
|
Nagasawa S, Maeda I, Fukuda T, Wu W,
Hayami R, Kojima Y, Tsugawa K and Ohta T: MED12 exon 2 mutations in
phyllodes tumors of the breast. Cancer Med. 4:1117–1121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Shaikhibrahim Z, Menon R, Braun M,
Offermann A, Queisser A, Boehm D, Vogel W, Rüenauver K, Ruiz C,
Zellweger T, et al: MED15, encoding a subunit of the mediator
complex, is overexpressed at high frequency in castration-resistant
prostate cancer. Int J Cancer. 135:19–26. 2014. View Article : Google Scholar : PubMed/NCBI
|
40
|
Kämpjärvi K, Mäkinen N, Kilpivaara O,
Arola J, Heinonen HR, Böhm J, Abdel-Wahab O, Lehtonen HJ, Pelttari
LM, Mehine M, et al: Somatic MED12 mutations in uterine
leiomyosarcoma and colorectal cancer. Br J Cancer. 107:1761–1765.
2012. View Article : Google Scholar : PubMed/NCBI
|
41
|
Zhao M, Yang X, Fu Y, Wang H, Ning Y, Yan
J, Chen YG and Wang G: Mediator MED15 modulates transforming growth
factor beta (TGFβ)/Smad signaling and breast cancer cell
metastasis. J Mol Cell Biol. 5:57–60. 2013. View Article : Google Scholar
|
42
|
Jin F, Irshad S, Yu W, Belakavadi M,
Chekmareva M, Ittmann MM, Abate-Shen C and Fondell JD: ERK and AKT
signaling drive MED1 overexpression in prostate cancer in
association with elevated proliferation and tumorigenicity. Mol
Cancer Res. 11:736–747. 2013. View Article : Google Scholar : PubMed/NCBI
|
43
|
Li XH, Fang DN and Zeng CM: Knockdown of
MED19 by short hairpin RNA-mediated gene silencing inhibits
pancreatic cancer cell proliferation. Cancer Biother Radiopharm.
26:495–501. 2011. View Article : Google Scholar : PubMed/NCBI
|
44
|
Chen W, Rogatsky I and Garabedian MJ:
MED14 and MED1 differentially regulate target-specific gene
activation by the glucocorticoid receptor. Mol Endocrinol.
20:560–572. 2006. View Article : Google Scholar
|
45
|
Huang CY, Chou YH, Hsieh NT, Chen HH and
Lee MF: MED28 regulates MEK1-dependent cellular migration in human
breast cancer cells. J Cell Physiol. 227:3820–3827. 2012.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Conaway RC and Conaway JW: Function and
regulation of the Mediator complex. Curr Opin Genet Dev.
21:225–230. 2011. View Article : Google Scholar : PubMed/NCBI
|